211 related articles for article (PubMed ID: 24962331)
1. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
[TBL] [Abstract][Full Text] [Related]
2. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.
Qi W; Xie C; Li C; Caldwell JT; Edwards H; Taub JW; Wang Y; Lin H; Ge Y
J Hematol Oncol; 2014 Aug; 7():53. PubMed ID: 25084614
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
Qi W; Zhang W; Edwards H; Chu R; Madlambayan GJ; Taub JW; Wang Z; Wang Y; Li C; Lin H; Ge Y
Cancer Biol Ther; 2015; 16(12):1784-93. PubMed ID: 26529495
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
6. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A
Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782
[TBL] [Abstract][Full Text] [Related]
7. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
Schenk EL; Koh BD; Flatten KS; Peterson KL; Parry D; Hess AD; Smith BD; Karp JE; Karnitz LM; Kaufmann SH
Clin Cancer Res; 2012 Oct; 18(19):5364-73. PubMed ID: 22869869
[TBL] [Abstract][Full Text] [Related]
8. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.
Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z
Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.
Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC
Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Webster JA; Tibes R; Morris L; Blackford AL; Litzow M; Patnaik M; Rosner GL; Gojo I; Kinders R; Wang L; Doyle LA; Huntoon CJ; Karnitz LM; Kaufmann SH; Karp JE; Smith BD
Leuk Res; 2017 Oct; 61():108-116. PubMed ID: 28957699
[TBL] [Abstract][Full Text] [Related]
11. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
[TBL] [Abstract][Full Text] [Related]
12. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
[TBL] [Abstract][Full Text] [Related]
13. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
14. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H
Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y
Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.
Russell MR; Levin K; Rader J; Belcastro L; Li Y; Martinez D; Pawel B; Shumway SD; Maris JM; Cole KA
Cancer Res; 2013 Jan; 73(2):776-84. PubMed ID: 23135916
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
18. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
20. Targeting of Carbon Ion-Induced G2 Checkpoint Activation in Lung Cancer Cells Using Wee-1 Inhibitor MK-1775.
Ma H; Takahashi A; Sejimo Y; Adachi A; Kubo N; Isono M; Yoshida Y; Kanai T; Ohno T; Nakano T
Radiat Res; 2015 Dec; 184(6):660-9. PubMed ID: 26645158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
